Insights
Search Results
News Articles
6.18.26
Wilson Sonsini Attorneys Named to Lawdragon’s 2026 500 Leading Global IP Lawyers Guide
On June 18, 2026, Lawdragon published the 2026 edition of its 500 Leading Global IP Lawyers guide, recognizing the leading attorneys that are protecting innovation, defending brand integrity, and leveraging the assets at the heart of their clients' businesses. Wilson Sonsini partners Wendy Devine, Jordan Jaffe, David Kramer, and James Yoon have been named to the 2026 guide.
Alerts
6.08.26
U.S. Supreme Court Addresses Liability for Patent Infringement by Generic Pharmaceuticals
In a unanimous opinion by Justice Ketanji Brown Jackson, the U.S. Supreme Court held that Amarin, the developer of Vascepa® (reference listed drug), failed to plausibly allege that Hikma actively induced infringement of Amarin’s method of use patents based on Hikma’s statements and materials related to its generic version of Vascepa®, reversing the decision by the U.S. Court of Appeals for the Federal Circuit (Federal Circuit). Although much of the import of this decision will not be fully understood until lower courts interpret this ruling, the Supreme Court provided guidance regarding one of the requirements for alleging a claim for induced patent infringement—one must plausibly allege that the defendant actively encouraged infringing use, not merely whether others could plausibly read statements by the defendant as instructions to infringe.
News Articles
2.17.26
WIPR Recognizes Wilson Sonsini in USA Patent Rankings 2025
World Intellectual Property Review (WIPR) recognized Wilson Sonsini’s patents practice in the 2025 edition of “WIPR USA Patents,” a comprehensive analysis of the leading law firms and attorneys in the U.S. Wilson Sonsini is ranked as a “Recommended Firm” and is noted for its patent work and for its bench of deeply knowledgeable practitioners. The firm is also recognized for its work in cutting-edge technology sectors, including artificial intelligence and machine learning.
Newsletters
1.08.26
Litigation Trends to Watch in 2026
Entering 2026, Wilson Sonsini litigators see a landscape defined by AI driven disputes, continued tightening of patent review standards, renewed securities and governance litigation, stronger consumer and influencer enforcement, and escalating Telephone Consumer Protection Act (TCPA) exposure—trends that require companies to align legal strategy with technical and operational controls.
Client Highlights
12.02.25
Wilson Sonsini Secures PTAB Institution in Five IPRs Filed for Azurity Pharmaceuticals
On November 19, 2025, Wilson Sonsini obtained a significant milestone for Azurity Pharmaceuticals, with the Patent Trial and Appeal Board (PTAB) instituting inter partes review in all five petitions the firm filed on Azurity’s behalf. The petitions challenge methods and compositions for treating chemotherapy-induced nausea and vomiting. The Board’s institution decisions found a reasonable likelihood that Azurity will prevail on at least one challenged claim in each proceeding and authorized full trials on the grounds raised. The Board’s decisions are a notable milestone in the current PTAB environment, where institution rates have tightened significantly. Three Administrative Patent Judges independently concluded the challenges were reasonably likely to succeed, and the cases will now proceed to the yearlong trial phase.
Client Highlights
10.08.25
Firm Advises Clearway on Acquisitions of Catalina Solar Facility and Deriva Energy’s Solar Portfolio
On October 6, 2025, Clearway Energy, Inc., one of the largest owners of clean energy generation assets in the U.S., announced that it has entered into a binding agreement to acquire a 613MWac portfolio of operating solar assets from Deriva Energy spanning eight states. Clearway also recently announced its acquisition of the 109 MW Catalina Solar facility in Kern County, California. Wilson Sonsini Goodrich & Rosati advised Clearway on the transactions.
Client Highlights
10.01.25
Wilson Sonsini Defends Win in Xarelto Appeal
On September 23, 2025, the U.S. Court of Appeals affirmed a decision of the Patent Trial and Appeal Board (PTAB) holding key patent claims covering Bayer's Xarelto product unpatentable. Wilson Sonsini represented Mylan Pharmaceuticals in the challenge before the PTAB and at the Federal Circuit.
News Articles
9.05.25
2026 Lawdragon 500 Leading Litigators in America Recognizes Wilson Sonsini Attorneys
On September 5, 2025, Lawdragon named 32 Wilson Sonsini attorneys to its 2026 edition of Leading Litigators in America. The lawyers featured in the guide represent the best litigators in the U.S. in antitrust, intellectual property, white collar and investigations, securities and corporate governance litigation, and a vast array of class actions, product liability, and other complex civil litigation.
News Articles
5.28.25
Lawdragon Names Firm Attorneys to Inaugural “500 Leading Global IP Lawyers” List
On May 23, 2025, Lawdragon introduced its inaugural edition of Lawdragon 500 Leading Global IP Lawyers, recognizing the leading attorneys that are working with entrepreneurs to nurture patent portfolios, monetize and license them, protect trade secrets, and engage in the highest profile litigation over technology, trademarks, and more. Wilson Sonsini partners Wendy Devine, Jordan Jaffe, David Kramer, and James Yoon have been named to this year's guide.
News Articles
4.02.25
Wendy Devine Recognized Among Daily Journal's 2025 Top IP Lawyers
On April 2, 2025, Wilson Sonsini litigation partner Wendy Devine was recognized in Daily Journal’s special report "Top Intellectual Property Lawyers 2025," an annual list honoring California's top lawyers specializing in patent litigation, trademark, and copyright. Wendy has built an 18-year career in intellectual property law, specializing in complex patent litigation for innovative companies across pharmaceuticals and food technology sectors.
Client Highlights
3.14.25
Wilson Sonsini Advises Azurity on Litigation Matters Related to Covis Pharma Acquisition
On March 14, 2025, Azurity Pharmaceuticals announced the successful completion of its acquisition of Covis from existing investors. With this acquisition, Covis is now a wholly owned subsidiary of Azurity. Wilson Sonsini Goodrich & Rosati advised Azurity on litigation matters related to the transaction.